WuXi Biologics (Cayman) (FRA:1FW2) Other Long-Term Liabilities : €140 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Other Long-Term Liabilities?

WuXi Biologics (Cayman)'s other long-term liabilities for the quarter that ended in Dec. 2023 was €140 Mil.

WuXi Biologics (Cayman)'s quarterly other long-term liabilities declined from Dec. 2022 (€146 Mil) to Jun. 2023 (€141 Mil) and declined from Jun. 2023 (€141 Mil) to Dec. 2023 (€140 Mil).

WuXi Biologics (Cayman)'s annual other long-term liabilities increased from Dec. 2021 (€139 Mil) to Dec. 2022 (€146 Mil) but then declined from Dec. 2022 (€146 Mil) to Dec. 2023 (€140 Mil).

WuXi Biologics (Cayman) Other Long-Term Liabilities Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Other Long-Term Liabilities Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial													-	-	-	-	-

WuXi Biologics (Cayman) Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

WuXi Biologics (Cayman) Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines